secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001213900-25-103509
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q4 net loss $12.1M ($0.28/shr); cash $52.8M; Cyclo Phase 3 continues
--------------------------------------------------------------------------------

- Net loss attributable to Rafael Holdings of $12.1M for Q4 vs $4.5M year ago; FY net loss $30.5M ($1.04/shr).
- Research and development expenses rose to $7.5M in Q4 from $1.5M year ago on Cyclo Therapeutics consolidation.
- Closed $25M rights offering in June 2025, including $21M backstop from the Jonas family; cash $52.8M at July 31.
- Cyclo’s Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 continues after DMC review at 48 weeks.
- Joshua Fine elected Chief Operating Officer effective August 4, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/0001213900-25-103509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea0262926-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-103509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer